Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Has $19.42 Million Stake in Pfizer Inc. (PFE)

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp reduced its stake in Pfizer Inc. (NYSE:PFE) by 2.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 535,300 shares of the biopharmaceutical company’s stock after selling 14,100 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Pfizer were worth $19,421,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Fort L.P. acquired a new stake in Pfizer in the second quarter valued at $121,000. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Pfizer in the first quarter valued at $132,000. Braun Bostich & Associates Inc. acquired a new stake in Pfizer in the first quarter valued at $139,000. Clearwater Capital Advisors LLC acquired a new stake in Pfizer in the first quarter valued at $156,000. Finally, Goodwin Daniel L purchased a new position in shares of Pfizer during the second quarter worth about $171,000. Institutional investors and hedge funds own 68.64% of the company’s stock.

NYSE PFE opened at $46.23 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a 52-week low of $33.20 and a 52-week high of $46.26. The stock has a market cap of $270.91 billion, a P/E ratio of 15.27, a P/E/G ratio of 2.27 and a beta of 0.88.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter last year, the company posted $0.67 earnings per share. The business’s revenue was up 1.0% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.

In related news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Several equities analysts have issued reports on the company. Atlantic Securities reaffirmed a “buy” rating and set a $54.00 price objective on shares of Pfizer in a report on Tuesday. Credit Suisse Group set a $42.00 price objective on Pfizer and gave the stock a “hold” rating in a report on Monday, November 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price objective on shares of Pfizer in a report on Monday, November 19th. Citigroup raised their price objective on Pfizer from $34.00 to $37.00 and gave the stock a “sell” rating in a report on Tuesday, November 6th. Finally, BMO Capital Markets lowered Pfizer from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $47.00 to $46.00 in a report on Thursday, November 1st. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $43.27.

TRADEMARK VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/12/01/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-has-19-42-million-stake-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: The Structure of a Futures Contract

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit